Stock listing
gettex:CHY ChemoMetec A/S Aktie
German listing (gettex) of ChemoMetec A/S · home listing Copenhagen:CHEMM
Follow ChemoMetec A/S into a list and get an email when it puts out news.
Home listing price · OMXCOP:CHEMM
682.00 DKK -12.50 (-1.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXCOP:CHEMM
- Day range
- 680.50 – 698.00 DKKNov 20, 2026
- Volume
- 45,436 sharesNov 20, 2026
- Market cap
- 11.70B DKKAt the close on Nov 20, 2026 · price × 17.16M shares outstanding
- 52-week range
- 235.20 – 788.00 DKKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 36.92M DKKMedian day 49,120 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Copenhagen:CHEMM · Home | 682.00 DKK | -12.50 (-1.8%) | 45,436 | 695.00 | 698.00 | 680.50 | 694.50 | Close on Nov 20, 2026 |
| Frankfurt:CHY | €89.65 EUR | -3.00 (-3.2%) | — | €91.50 | €92.30 | €89.65 | €92.65 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXCOP:CHEMM · DKK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 682.00 | -12.50 | -1.8% | 695.00 | 698.00 | 680.50 | 45,436 | |
| 694.50 | +6.50 | +0.9% | 690.00 | 702.50 | 688.00 | 38,800 | |
| 688.00 | -10.00 | -1.4% | 695.00 | 695.50 | 682.50 | 38,692 | |
| 698.00 | +9.50 | +1.4% | 688.50 | 704.00 | 687.50 | 37,986 | |
| 688.50 | +3.50 | +0.5% | 684.00 | 699.50 | 684.00 | 46,039 | |
| 685.00 | -23.50 | -3.3% | 710.50 | 720.00 | 681.00 | 88,741 | |
| 708.50 | -18.00 | -2.5% | 724.00 | 728.00 | 708.00 | 46,305 | |
| 726.50 | +20.50 | +2.9% | 724.50 | 744.50 | 722.00 | 74,691 | |
| 706.00 | +34.50 | +5.1% | 670.00 | 713.50 | 661.50 | 118,650 | |
| 671.50 | +26.50 | +4.1% | 660.00 | 679.00 | 640.00 | 75,730 | |
| 645.00 | -9.50 | -1.5% | 648.00 | 661.50 | 643.00 | 66,853 | |
| 654.50 | +35.00 | +5.6% | 613.00 | 656.50 | 596.50 | 180,602 | |
| 619.50 | +8.50 | +1.4% | 623.00 | 639.00 | 617.50 | 48,102 | |
| 611.00 | -10.00 | -1.6% | 623.00 | 626.50 | 609.50 | 24,975 | |
| 621.00 | +11.00 | +1.8% | 608.00 | 622.50 | 601.50 | 38,128 | |
| 610.00 | +2.00 | +0.3% | 614.00 | 619.50 | 603.00 | 33,649 | |
| 608.00 | -1.50 | -0.2% | 611.50 | 615.00 | 604.00 | 27,720 | |
| 609.50 | +17.00 | +2.9% | 591.00 | 611.50 | 587.50 | 41,261 | |
| 592.50 | -2.50 | -0.4% | 594.00 | 594.00 | 576.00 | 27,684 | |
| 595.00 | -1.50 | -0.3% | 596.50 | 601.50 | 587.00 | 34,130 | |
| 596.50 | +20.50 | +3.6% | 578.00 | 596.50 | 578.00 | 51,626 | |
| 576.00 | +9.00 | +1.6% | 569.50 | 580.00 | 568.00 | 42,516 | |
| 567.00 | -2.00 | -0.4% | 571.00 | 578.50 | 561.50 | 37,309 | |
| 569.00 | -7.00 | -1.2% | 576.00 | 581.50 | 569.00 | 26,270 | |
| 576.00 | -5.00 | -0.9% | 580.50 | 583.50 | 572.50 | 33,750 | |
| 581.00 | +12.00 | +2.1% | 569.50 | 587.50 | 569.00 | 49,120 | |
| 569.00 | -15.50 | -2.7% | 584.50 | 587.00 | 568.50 | 56,684 | |
| 584.50 | -2.00 | -0.3% | 587.50 | 592.00 | 578.50 | 34,278 | |
| 586.50 | +31.00 | +5.6% | 560.50 | 589.00 | 560.50 | 60,052 | |
| 555.50 | -12.00 | -2.1% | 568.00 | 581.00 | 555.50 | 58,952 | |
| 567.50 | -12.50 | -2.2% | 580.50 | 587.00 | 563.00 | 71,114 | |
| 580.00 | -5.00 | -0.9% | 593.00 | 607.00 | 580.00 | 81,481 | |
| 585.00 | +34.50 | +6.3% | 552.50 | 606.00 | 549.50 | 173,972 | |
| 550.50 | +31.50 | +6.1% | 520.00 | 554.00 | 508.00 | 83,079 | |
| 519.00 | -4.00 | -0.8% | 524.50 | 525.50 | 513.50 | 28,137 | |
| 523.00 | +3.50 | +0.7% | 521.50 | 526.50 | 518.00 | 43,235 | |
| 519.50 | -3.00 | -0.6% | 523.50 | 525.50 | 511.00 | 65,731 | |
| 522.50 | +7.50 | +1.5% | 518.00 | 525.00 | 517.00 | 43,631 | |
| 515.00 | -10.00 | -1.9% | 525.50 | 529.00 | 511.50 | 35,844 | |
| 525.00 | +8.50 | +1.6% | 514.00 | 525.00 | 511.00 | 26,675 | |
| 516.50 | +1.50 | +0.3% | 515.00 | 525.00 | 515.00 | 28,368 | |
| 515.00 | -10.00 | -1.9% | 525.50 | 525.50 | 513.00 | 45,017 | |
| 525.00 | +15.00 | +2.9% | 510.50 | 533.00 | 510.50 | 106,089 | |
| 510.00 | -11.50 | -2.2% | 522.00 | 526.50 | 504.00 | 79,246 | |
| 521.50 | +20.00 | +4.0% | 505.50 | 521.50 | 500.50 | 58,916 | |
| 501.50 | +9.10 | +1.8% | 493.80 | 511.00 | 493.40 | 72,396 | |
| 492.40 | +9.40 | +1.9% | 483.00 | 492.40 | 473.00 | 94,837 | |
| 483.00 | -9.80 | -2.0% | 492.80 | 498.80 | 476.00 | 86,879 | |
| 492.80 | -29.70 | -5.7% | 487.80 | 515.00 | 464.40 | 325,515 | |
| 522.50 | +7.50 | +1.5% | 517.00 | 525.00 | 513.00 | 67,015 | |
| 515.00 | -3.50 | -0.7% | 522.00 | 528.00 | 507.00 | 123,997 | |
| 518.50 | +5.50 | +1.1% | 513.00 | 535.50 | 511.00 | 132,510 | |
| 513.00 | +3.00 | +0.6% | 510.00 | 519.50 | 509.00 | 39,506 | |
| 510.00 | -6.50 | -1.3% | 523.00 | 526.00 | 509.00 | 41,614 | |
| 516.50 | +34.70 | +7.2% | 505.00 | 532.00 | 505.00 | 137,240 | |
| 481.80 | +6.80 | +1.4% | 472.00 | 482.80 | 465.20 | 97,001 | |
| 475.00 | -21.60 | -4.3% | 495.60 | 495.60 | 470.20 | 70,115 | |
| 496.60 | -7.40 | -1.5% | 501.00 | 507.50 | 495.00 | 45,602 | |
| 504.00 | +2.50 | +0.5% | 500.50 | 508.50 | 500.50 | 44,344 | |
| 501.50 | +9.50 | +1.9% | 490.40 | 503.50 | 490.00 | 24,907 | |
| 492.00 | -4.80 | -1.0% | 496.80 | 500.00 | 490.00 | 24,262 | |
| 496.80 | +9.80 | +2.0% | 489.00 | 501.00 | 489.00 | 99,054 | |
| 487.00 | -0.40 | -0.1% | 478.00 | 490.80 | 469.60 | 63,076 | |
| 487.40 | +12.20 | +2.6% | 478.00 | 494.80 | 476.20 | 51,370 | |
| 475.20 | -7.80 | -1.6% | 482.20 | 492.00 | 414.20 | 82,848 |
- Ticker
- gettex:CHY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Sep 10, 2026
Guidance for the 2026/27 financial year
Latest news
Guidance for the 2026/27 financial year
Sep 10, 2026
Closed 492.80 (-5.7%) on Sep 11, 2026
ChemoMetec enters collaboration agreement with Roche Diagnostics
Aug 10, 2026
Closed 466.40 (+8.5%) on Aug 10, 2026
ChemoMetec A/S invites to conference call on September 11, 2026 at 3: 00 p.m. CEST on its upcoming 2025/26 Annual Report
Aug 7, 2026
Closed 430.00 (+3.6%) on Aug 7, 2026
Initiation of buy-back programme
May 15, 2026
Closed 323.20 (+3.1%) on May 18, 2026
Adjustment of accounting estimates contributes to an upgrade of revenue and operating profit guidance
May 4, 2026
Closed 323.40 (-0.8%) on May 4, 2026
Notification of managers’ transactions
Mar 27, 2026
Closed 290.00 (-2.4%) on Mar 27, 2026
Adjustment of guidance for 2025/26
Mar 24, 2026
Closed 280.60 (+18.5%) on Mar 25, 2026
Notification of managers' transactions
Mar 2, 2026
Closed 411.00 (-2.2%) on Mar 2, 2026
ChemoMetec enters Letter of Intent with Roche Diagnostics
Feb 4, 2026
Closed 463.00 (-20.1%) on Feb 5, 2026
Interim report 2025/26 - Organic growth despite challenges in the North American market
Feb 4, 2026
Closed 463.00 (-20.1%) on Feb 5, 2026
ChemoMetec A/S on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 10 in the last 12 months · 19 in all · newest Sep 10, 2026 · oldest 2025
- Decks
- 1 deck · latest Feb 6, 2024
Where ChemoMetec A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Copenhagen:CHEMM · Home listing | Copenhagen | Denmark | DKK |
| gettex:CHY · This page | gettex | Germany | EUR |
| LSIN:0DZ0 | LSIN | United Kingdom | DKK |
| Tradegate:CHY | Tradegate | Germany | EUR |
| LS Exchange:A0MS80 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A0MS80 | Lang & Schwarz | Germany | EUR |
| Frankfurt:CHY | Frankfurt | Germany | EUR |
| Aquis:CHEMMC | Aquis | United Kingdom | DKK |
| Stuttgart:CHY | Stuttgart | Germany | EUR |
| OTC:CHHMF | OTC | United States | USD |
| Munich:CHY | Munich | Germany | EUR |
| Aquis:CHEMMC | Aquis | United Kingdom | DKK |
| Dusseldorf:CHY | Dusseldorf | Germany | EUR |
| Hamburg:CHY | Hamburg | Germany | EUR |
| Turquoise:CHEMMC | Turquoise | United Kingdom | DKK |
Valuation
P/E 58.0× against a median of 76.0×: 3rd lowest of 5 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 11.42B DKK
- P/E
- 58.0×
- EV/sales
- 22.3×
- EV/EBITDA
- 40.6×
- Price/book
- 16.1×
- Gross margin
- 95.1%
- Operating margin
- 49.1%
- Net margin
- 39.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ChemoMetec A/S · OMXCOP:CHEMM | US$1.72B | US$1.68B | 58.0× | 22.3× | 40.6× | 16.1× | 39.5% | 0.0× | n/a |
| OneSource Specialty Pharma Limited · NSE:ONESOURCE | US$1.99B | US$2.18B | n/a | 12.0× | 50.9× | 3.1× | −0.1% | 0.3× | n/a |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A · SSE:603456 | US$1.98B | US$1.78B | 22.0× | 2.2× | n/a | 1.5× | 11.3% | 0.0× | n/a |
| Azenta, Inc. · NASDAQ:AZTA | US$1.96B | US$1.63B | n/a | 2.6× | n/a | 1.4× | −26.9% | 0.0× | 1.59 |
| Syngene International Ltd. · NSE:SYNGENE | US$1.96B | US$1.96B | 97.5× | 5.2× | 20.0× | 3.7× | 5.3% | 0.1× | n/a |
| Cohance Lifesciences Ltd · NSE:COHANCE | US$1.91B | US$1.88B | 167× | 8.1× | 55.1× | 4.5× | 5.0% | 0.1× | n/a |
| Alamar Biosciences, Inc. · NASDAQ:ALMR | US$1.84B | US$1.66B | n/a | 14.5× | n/a | 6.1× | −48.2% | 0.1× | 1.70 |
| Fortrea Holdings Inc. · NASDAQ:FTRE | US$1.79B | US$2.62B | n/a | 1.0× | 28.7× | 3.4× | −2.6% | 2.0× | 1.68 |
| GemPharmatech Co., Ltd. Class A · SSE:688046 | US$1.65B | US$1.49B | 54.4× | 10.5× | n/a | 4.7× | 21.5% | 0.0× | n/a |
| PolyPeptide Group AG · SIX:PPGN | US$1.62B | US$1.70B | n/a | 4.0× | 34.1× | 4.2× | −5.4% | 0.4× | n/a |
| Personalis, Inc. · NASDAQ:PSNL | US$1.55B | US$1.39B | n/a | 17.3× | n/a | 7.3× | −147.7% | 0.2× | 2.03 |
| Median of the others | US$1.87B | US$1.74B | 76.0× | 6.7× | 34.1× | 4.0× | −1.3% | 0.1× | 1.69 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 780.00 DKK · Analysts' mean
- EPS, year to Jun 2027
- 14.64 · 3 analysts
- Revenue, year to Jun 2027
- 607M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Martin Helbo Behrens | CEO |
| Phillip Massie Price | CFO |
| Andrey Gorin | Laboratory Manager |
| Glenn Winnier | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Niels Thestrup | Chairman of the Board |
| Betina Hagerup | Member of the Board of Directors |
| Kristine Færch | Member of the Board of Directors |
| Martin Glensbjerg | Deputy Chairman |
| Peter Reich | Member of the Board of Directors |
Events
- Next results
- Feb 2, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2025 | May 7, 2025 | −5.4% |
| Q2 2025 | Feb 5, 2025 | +5.6% |
| Quarter to Sep 30, 2024 | Nov 7, 2024 | +29.8% |
| Q4 2024 | Sep 11, 2024 · After close | +0.2% |
| Q3 2024 | May 8, 2024 · Before open | −0.6% |
| Q2 2024 | Feb 5, 2024 · After close | +24.0% |
| Q1 2024 | Nov 7, 2023 · After close | +7.5% |
| Q4 2023 | Sep 13, 2023 · After close | −4.4% |
| Q3 2023 | May 9, 2023 | +4.1% |
| Q2 2023 | Feb 9, 2023 | −22.1% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | Nov 8, 2022 · After close | +0.4% |
| Q4 2022 | Sep 15, 2022 · Before open | +0.2% |
| Q3 2022 | May 5, 2022 · Before open | +0.8% |
| Q2 2022 | Feb 8, 2022 · After close | +3.8% |
| Q1 2022 | Nov 4, 2021 · Before open | +0.4% |
| Q4 2021 | Sep 15, 2021 · After close | +3.0% |
| Q3 2021 | May 6, 2021 | −4.3% |
| Q2 2021 | Feb 5, 2021 · After close | +3.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2023/24 Earnings Presentation | Earnings | 14 slides | Feb 6, 2024 |
Financials
Annual, in DKK
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 511.1M | 495.6M | 407.4M | 444.4M | 428.4M | 281.1M | 214.1M | 175.5M | 112.7M | 90.3M |
| Cost of revenue | 25.1M | 30.1M | 40.3M | 49.0M | 44.1M | 27.8M | 20.2M | 16.9M | 13.2M | 10.1M |
| Gross profit | 486.0M | 465.5M | 367.6M | 395.4M | 384.3M | 253.3M | 193.9M | 158.6M | 99.5M | 80.2M |
| Research and development | 15.4M | 10.4M | 8.39M | 7.16M | 7.23M | 6.49M | 6.48M | 5.69M | 3.69M | 3.80M |
| Selling, general and administrative | 41.3M | 23.4M | 25.7M | 24.1M | 20.3M | 20.2M | ||||
| Operating income | 251.0M | 236.5M | 169.0M | 228.5M | 201.5M | 116.0M | 77.5M | 54.1M | 24.3M | 10.4M |
| Depreciation and amortization | 30.3M | 21.5M | 17.2M | 20.4M | 20.0M | 19.6M | 15.1M | 10.8M | 5.79M | 5.45M |
| EBITDA | 281.3M | 258.0M | 186.2M | 248.9M | 221.6M | 135.6M | 92.6M | 64.9M | 30.1M | 15.9M |
| Interest expense | 392.0K | 17.4M | 1.28M | 1.09M | 1.52M | 918.0K | 1.19M | 716.0K | 887.0K | 1.07M |
| Income before tax | 258.2M | 225.0M | 176.6M | 230.4M | 203.2M | 112.7M | 75.9M | 53.7M | 23.3M | 8.65M |
| Income tax | 56.3M | 50.3M | 40.3M | 51.7M | 43.8M | 24.4M | 16.8M | 11.9M | 5.09M | 1.17M |
| Net income | 201.8M | 174.7M | 136.3M | 178.7M | 159.5M | 88.4M | 59.2M | 41.8M | 18.2M | 7.49M |
| Earnings per share, basic | 11,600.00 | 10,040.00 | 7.83 | 10.27 | 9.16 | 5.08 | 3.51 | 2.69 | 1.17 | 0.48 |
| Earnings per share, diluted | 11,600.00 | 10,040.00 | 7.83 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 290.2M | 341.8M | 296.1M | 316.6M | 209.0M | 150.1M | 96.9M | 98.2M | 9.78M | 12.4M |
| Short-term investments | 3.39M | -93.8M | -82.6M | |||||||
| Receivables | 99.2M | 79.6M | 69.1M | 59.7M | 65.9M | 62.6M | 44.3M | 36.0M | 19.6M | 14.7M |
| Inventory | 126.2M | 120.8M | 119.5M | 112.6M | 66.8M | 30.1M | 25.1M | 19.5M | 16.8M | 13.3M |
| Current assets | 524.8M | 554.6M | 489.8M | 492.7M | 352.9M | 244.4M | 168.3M | 154.8M | 46.8M | 41.0M |
| Property, plant and equipment | 126.6M | 115.6M | 92.0M | 82.7M | 74.8M | 42.5M | 43.4M | 38.1M | 28.9M | 26.4M |
| Goodwill | 7.36M | 7.35M | 0 | |||||||
| Total assets | 860.9M | 839.5M | 676.7M | 658.0M | 501.3M | 344.9M | 263.1M | 238.2M | 114.0M | 97.6M |
| Accounts payable | 38.1M | 16.1M | 11.1M | 17.6M | 17.0M | 8.71M | 8.43M | 9.71M | 7.26M | 4.89M |
| Current liabilities | 128.2M | 143.7M | 98.5M | 119.2M | 137.4M | 72.0M | 47.7M | 55.0M | 17.9M | 21.1M |
| Long-term debt | 0 | 17.8M | 10.9M | |||||||
| Total debt | 4.59M | 6.40M | 4.16M | 7.16M | 6.79M | 2.36M | 2.29M | 18.8M | 20.1M | 22.1M |
| Total liabilities | 135.5M | 151.4M | 111.4M | 124.9M | 144.1M | 79.9M | 60.4M | 64.9M | 41.0M | 33.2M |
| Shareholders' equity | 725.4M | 688.1M | 565.3M | 533.0M | 357.2M | 265.0M | 202.8M | 173.3M | 73.0M | 64.4M |
| Shares outstanding | 17.4M | 17.4M | 17.4M | 17.4M | 17.4M | 17.4M | 16.9M | 15.6M | 15.5M | 15.7M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 210.4M | 207.4M | 129.0M | 154.1M | 176.9M | 107.9M | 72.0M | 58.3M | 25.4M | 9.76M |
| Capital spending | -28.3M | -29.9M | -20.9M | -40.8M | -55.9M | -24.6M | -26.7M | -27.1M | -16.5M | -10.6M |
| Free cash flow | 182.0M | 177.6M | 108.1M | 113.3M | 120.9M | 83.3M | 45.3M | 31.2M | 8.97M | -833.0K |
| Cash from investing | -99.8M | -85.5M | -43.5M | -40.8M | -56.0M | -24.7M | -26.6M | -27.1M | -16.5M | -10.3M |
| Cash from financing | -161.6M | -75.0M | -105.7M | -2.92M | -69.0M | -26.0M | -46.3M | 57.8M | -7.93M | -355.0K |
| Dividends paid | -121.8M | -69.6M | -104.4M | -69.6M | -26.1M | -348.1M | -136.0M | -136.0M | -136.0M | |
| Share buybacks | -38.6M | 1.87M | -9.57M | |||||||
| Change in cash | -51.0M | 47.0M | -20.2M | 107.5M | 58.9M | 53.2M | -1.25M | 89.0M | 933.0K | -1.70M |
Cap table
Built by 6ix from ChemoMetec A/S’ releases
- Common shares
- 17,162,529
- Fully diluted
- 17,162,529
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 17,162,529 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 17,162,529 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Betina Hagerup | Member of the Board of Directors · Since at least Mar 2, 2026 |
| Kristine Færch | Member of the Board of Directors · Since at least Oct 9, 2025 |
| Martin Glensbjerg | Deputy Chairman · Since at least Oct 9, 2025 |
| Martin Helbo Behrens | CEO · Since at least Sep 10, 2026 |
| Niels Thestrup | Chairman of the Board · Since at least Oct 9, 2025 |
| Peter Reich | Member of the Board of Directors · Since at least Oct 9, 2025 |
| Phillip Massie Price | CFO · Since at least Sep 10, 2026 |
Log in to ask 6ix AI your own questions about ChemoMetec A/S.